Activin receptor modulation

Anna Mies, Amit Verma, Uwe Platzbecker

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Conventional treatment regimen of lower-risk MDS with erythropoiesis-stimulating agents often fails to induce sustained erythroid improvement in these patients that frequently harbor defects in late-stage erythroblasts downstream of erythropoietin action. Thus, alternative treatment options that would achieve sustainable transfusion independence are needed. In this chapter, we will discuss activin receptor ligand traps as novel therapeutic strategies for low-risk MDS subgroups that were recently shown to alleviate anemia by specifically inhibiting aberrant TGF-β signaling and thereby promoting erythroid differentiation.

Original languageEnglish (US)
Title of host publicationHematologic Malignancies
PublisherSpringer Verlag
Pages97-104
Number of pages8
DOIs
StatePublished - 2018

Publication series

NameHematologic Malignancies
ISSN (Print)2197-9766
ISSN (Electronic)2197-9774

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Activin receptor modulation'. Together they form a unique fingerprint.

Cite this